Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
38.05
-0.19 (-0.50%)
Mar 13, 2025, 4:00 PM EST - Market closed
Legend Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 620.98 | 284.96 | 116.68 | 65.4 | 75 | Upgrade
|
| Other Revenue | 6.26 | 0.18 | 0.33 | 3.42 | - | Upgrade
|
| Revenue | 627.24 | 285.14 | 117.01 | 68.83 | 75 | Upgrade
|
| Revenue Growth (YoY) | 119.97% | 143.70% | 70.00% | -8.23% | 21.36% | Upgrade
|
| Cost of Revenue | 648.13 | 526.43 | 401.01 | 313.35 | 232.16 | Upgrade
|
| Gross Profit | -20.88 | -241.29 | -284.01 | -244.52 | -157.16 | Upgrade
|
| Selling, General & Admin | 284.26 | 200.93 | 174.05 | 149.5 | 72.71 | Upgrade
|
| Operating Expenses | 284.26 | 200.93 | 174.05 | 149.5 | 72.71 | Upgrade
|
| Operating Income | -305.15 | -442.22 | -458.05 | -394.02 | -229.87 | Upgrade
|
| Interest Expense | -21.62 | -21.79 | -10.8 | -0.9 | -0.2 | Upgrade
|
| Interest & Investment Income | 61.2 | 54.49 | 8.18 | 0.97 | 2.93 | Upgrade
|
| Currency Exchange Gain (Loss) | 109.35 | - | - | - | 0.07 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.51 | -111.03 | 14.82 | -12.27 | -1.23 | Upgrade
|
| EBT Excluding Unusual Items | -153.71 | -520.56 | -445.85 | -406.22 | -228.29 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.66 | 0.6 | - | 0.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0 | -0.23 | -0.48 | -0.97 | -0.06 | Upgrade
|
| Asset Writedown | -4.42 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -79.98 | Upgrade
|
| Pretax Income | -158.13 | -520.12 | -445.72 | -407.2 | -308.29 | Upgrade
|
| Income Tax Expense | 18.89 | -1.86 | 0.63 | -3.61 | -41.91 | Upgrade
|
| Net Income | -177.03 | -518.25 | -446.35 | -403.58 | -266.37 | Upgrade
|
| Net Income to Common | -177.03 | -518.25 | -446.35 | -403.58 | -266.37 | Upgrade
|
| Shares Outstanding (Basic) | 183 | 176 | 159 | 141 | 118 | Upgrade
|
| Shares Outstanding (Diluted) | 183 | 176 | 159 | 141 | 118 | Upgrade
|
| Shares Change (YoY) | 3.84% | 10.71% | 12.91% | 19.21% | 18.15% | Upgrade
|
| EPS (Basic) | -0.97 | -2.94 | -2.81 | -2.87 | -2.25 | Upgrade
|
| EPS (Diluted) | -0.97 | -2.94 | -2.81 | -2.87 | -2.26 | Upgrade
|
| Free Cash Flow | -158.14 | -413.36 | -222.21 | -240.66 | -249.26 | Upgrade
|
| Free Cash Flow Per Share | -0.86 | -2.35 | -1.40 | -1.71 | -2.11 | Upgrade
|
| Gross Margin | -3.33% | -84.62% | -242.73% | - | -209.55% | Upgrade
|
| Operating Margin | -48.65% | -155.09% | -391.48% | -572.49% | -306.49% | Upgrade
|
| Profit Margin | -28.22% | -181.75% | -381.48% | -586.38% | -355.16% | Upgrade
|
| Free Cash Flow Margin | -25.21% | -144.97% | -189.91% | -349.67% | -332.35% | Upgrade
|
| EBITDA | -294.29 | -431.48 | -445.41 | -385.88 | -223.63 | Upgrade
|
| EBITDA Margin | -46.92% | -151.32% | - | - | -298.17% | Upgrade
|
| D&A For EBITDA | 10.86 | 10.73 | 12.65 | 8.14 | 6.23 | Upgrade
|
| EBIT | -305.15 | -442.22 | -458.05 | -394.02 | -229.87 | Upgrade
|
| EBIT Margin | -48.65% | -155.09% | - | - | - | Upgrade
|
| Revenue as Reported | 627.24 | 285.14 | 117.01 | 68.83 | 75 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.